Sucampo Pharmaceuticals Inc. (SCMP) Issues FY16 Earnings Guidance
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) issued an update on its FY16 earnings guidance on Wednesday morning. The company provided EPS guidance of $1.20-1.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.04. The company issued revenue guidance of $220-225 million, compared to the consensus revenue estimate of $205.65 million.
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) opened at 14.50 on Friday. The stock’s 50 day moving average price is $12.59 and its 200-day moving average price is $11.73. Sucampo Pharmaceuticals Inc. has a 1-year low of $9.59 and a 1-year high of $18.75. The company has a market cap of $616.24 million, a PE ratio of 19.86 and a beta of 1.62.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.02. Sucampo Pharmaceuticals had a return on equity of 42.18% and a net margin of 6.65%. The firm had revenue of $57.90 million for the quarter, compared to analysts’ expectations of $51.30 million. During the same period last year, the firm earned $0.16 EPS. The company’s quarterly revenue was up 73.4% on a year-over-year basis. On average, analysts forecast that Sucampo Pharmaceuticals Inc. will post $1.03 earnings per share for the current year.
A number of equities research analysts have recently commented on SCMP shares. Northland Securities started coverage on Sucampo Pharmaceuticals in a research report on Wednesday, September 7th. They set an outperform rating and a $15.00 target price on the stock. Vetr upgraded Sucampo Pharmaceuticals from a buy rating to a strong-buy rating and set a $14.00 price objective on the stock in a report on Thursday, September 29th. Maxim Group lowered their price objective on Sucampo Pharmaceuticals from $26.00 to $17.00 and set a buy rating on the stock in a report on Monday, August 1st. Mizuho cut Sucampo Pharmaceuticals from a buy rating to a neutral rating and set a $13.00 price objective on the stock. in a report on Thursday, August 4th. Finally, Jefferies Group lowered their price objective on Sucampo Pharmaceuticals from $16.00 to $14.00 and set a hold rating on the stock in a report on Thursday, August 4th. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $16.56.
Hedge funds have recently added to or reduced their stakes in the stock. Ativo Capital Management LLC purchased a new stake in Sucampo Pharmaceuticals during the second quarter valued at approximately $1,009,000. ProShare Advisors LLC raised its stake in Sucampo Pharmaceuticals by 1.0% in the second quarter. ProShare Advisors LLC now owns 36,954 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 369 shares during the last quarter. Rhumbline Advisers raised its stake in Sucampo Pharmaceuticals by 2.2% in the second quarter. Rhumbline Advisers now owns 26,930 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 580 shares during the last quarter. Perceptive Advisors LLC raised its stake in Sucampo Pharmaceuticals by 5,314.5% in the second quarter. Perceptive Advisors LLC now owns 41,096 shares of the biopharmaceutical company’s stock valued at $451,000 after buying an additional 40,337 shares during the last quarter. Finally, Raymond James & Associates raised its stake in Sucampo Pharmaceuticals by 12.0% in the second quarter. Raymond James & Associates now owns 16,603 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 1,781 shares during the last quarter. 38.91% of the stock is currently owned by hedge funds and other institutional investors.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.